Expertise in
1
conditions

Dr. Charles Fogarty

Pulmonary Medicine
Raed T Suleiman LLC
2030 N Church Street Pl, 
Spartanburg, SC 
Expertise in
1
conditions
Raed T Suleiman LLC
2030 N Church Street Pl, 
Spartanburg, SC 

Overview

Charles Fogarty is a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Fogarty is highly rated in 1 condition, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Lung Metastases, and Chronic Cough.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Raed T Suleiman LLC
2030 N Church Street Pl, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis
Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: June 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
Enrollment Status: Completed
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

20 Total Publications

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
Journal: The Lancet. Respiratory medicine
Published: May 29, 2024
Similar Doctors
Expertise in
26
conditions
Dr. Abbas H. Mansour
Pulmonary Medicine
Expertise in
26
conditions
Dr. Abbas H. Mansour
Pulmonary Medicine

Carolina Pulmonary & Sleep Disorder

201 Richard Street, 
Easley, SC 
 (38.9 miles away)
864-850-0700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Abbas Mansour is a Pulmonary Medicine provider in Easley, South Carolina. Dr. Mansour is highly rated in 26 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Atypical Pneumonia, Hospital-Acquired Pneumonia, and Gastrostomy. Dr. Mansour is currently accepting new patients.

Expertise in
5
conditions
Dr. David Erb
Pulmonary Medicine
Expertise in
5
conditions
Dr. David Erb
Pulmonary Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
 (1.1 miles away)
864-573-6320
Languages Spoken:
English
See accepted insurances

David Erb is a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Erb is highly rated in 5 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Pneumonia, and Advanced Bronchoscopy.

Expertise in
23
conditions
Dr. Charles Mullen
Pulmonary Medicine
Expertise in
23
conditions
Dr. Charles Mullen
Pulmonary Medicine

Palmetto Pulmonary And Critical Care

3 Francis Ste 300, 
Greenville, SC 
 (27.4 miles away)
864-233-8063
Languages Spoken:
English
See accepted insurances

Charles Mullen is a Pulmonary Medicine provider in Greenville, South Carolina. Dr. Mullen is highly rated in 23 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Hospital-Acquired Pneumonia, Atypical Pneumonia, and Gastrostomy.

Frequently Asked Questions about Dr. Charles Fogarty

How do I make an appointment with Dr. Charles Fogarty?

You can book an appointment with Dr. Charles Fogarty by calling their office at 864-582-6703. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles Fogarty a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles Fogarty is classified as an Advanced expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles Fogarty specialize in?

While Dr. Charles Fogarty is a Pulmonary Medicine, they have specific expertise in Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Lung Metastases. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Charles Fogarty participate in research or clinical trials?

Yes. Dr. Charles Fogarty has published 20 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Dr. Charles Fogarty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles Fogarty accept my insurance?

Dr. Charles Fogarty accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 864-582-6703 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fogarty's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile